switching between glp-1 agonists Mechanisms by which may exert beneficial effects on the Switching from tirzepatide to retatrutide:
Description
Approved in 2022 for diabetes (brand Mounjaro), tirzepatide produced extraordinary results in weight loss up to ~22% in obese participants at the highest dose in a phase 3 trial ( [137] )

This groundbreaking medication is shown to enhance therapeutic outcomes by delivering more pronounced reductions in both body weight and HbA1c levels than current pharmacotherapies

Increased FFA in the liver results in insulin resistance, hepatic glucose production, and pancreatic beta cell dysfunction [7]

In patients with cardiovascular diseases, clinical observations have demonstrated enhanced benefits of GLP-1RAs in treating prostate cancer

Woo AYH, Xiao R
